- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Most Popular Stocks
U.S. Pharmaceuticals & Biotech Most Popular Stocks
Results
1140
Most Popular Stocks on the market
1140 companies
MetaVia
Market Cap: US$24.2m
A clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases.
MTVA
US$0.97
7D
-6.7%
1Y
-70.8%
AccuStem Sciences
Market Cap: US$24.1m
A clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care.
ACUT
US$1.50
7D
8.7%
1Y
248.8%
Hoth Therapeutics
Market Cap: US$24.0m
A clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs.
HOTH
US$1.73
7D
-4.2%
1Y
89.7%
Lixte Biotechnology Holdings
Market Cap: US$23.9m
A clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies.
LIXT
US$5.06
7D
-7.2%
1Y
165.3%
Kairos Pharma
Market Cap: US$23.6m
A clinical-stage biopharmaceutical company, develops therapeutics for cancer patients.
KAPA
US$1.10
7D
-9.8%
1Y
-28.6%
Rallybio
Market Cap: US$23.6m
A clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
RLYB
US$0.55
7D
-6.6%
1Y
-50.2%
CASI Pharmaceuticals
Market Cap: US$23.4m
A biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally.
CASI
US$1.31
7D
-26.4%
1Y
-78.2%
Neuphoria Therapeutics
Market Cap: US$23.4m
A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia.
NEUP
US$12.31
7D
21.9%
1Y
n/a
Propanc Biopharma
Market Cap: US$23.1m
A development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia.
PPCB
US$1.82
7D
-15.7%
1Y
-89.9%
SenesTech
Market Cap: US$23.0m
Engages in the development and commercialization of a technology for managing animal pest populations through fertility control.
SNES
US$4.64
7D
-4.5%
1Y
84.9%
Q32 Bio
Market Cap: US$22.9m
A clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction.
QTTB
US$1.89
7D
2.2%
1Y
-95.9%
CytoMed Therapeutics
Market Cap: US$22.7m
A pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.
GDTC
US$1.99
7D
6.7%
1Y
28.4%
FibroBiologics
Market Cap: US$22.6m
Operates as a cell therapy, regenerative medicine company.
FBLG
US$0.57
7D
7.7%
1Y
-82.0%
NanoViricides
Market Cap: US$22.5m
A clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections.
NNVC
US$1.42
7D
-3.4%
1Y
-2.1%
Apimeds Pharmaceuticals US
Market Cap: US$22.4m
Operates as a clinical stage biopharmaceutical company in the United States.
APUS
US$1.93
7D
-4.5%
1Y
n/a
SAB Biotherapeutics
Market Cap: US$21.9m
A clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders.
SABS
US$2.01
7D
-18.6%
1Y
-21.8%
Protect Pharmaceutical
Market Cap: US$21.8m
Primarily focuses on crop farming and agricultural businesses.
PRTT
US$0.35
7D
-8.5%
1Y
-74.1%
Moleculin Biotech
Market Cap: US$21.8m
A late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses.
MBRX
US$0.49
7D
22.2%
1Y
-82.1%
Cingulate
Market Cap: US$21.2m
A biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.
CING
US$3.81
7D
7.6%
1Y
-24.3%
Lisata Therapeutics
Market Cap: US$20.7m
A clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.
LSTA
US$2.47
7D
6.0%
1Y
-15.1%
ProMIS Neurosciences
Market Cap: US$20.7m
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
PMN
US$0.41
7D
-7.4%
1Y
-68.1%
Curis
Market Cap: US$20.5m
A biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
CRIS
US$1.69
7D
-0.6%
1Y
-68.6%
Reviva Pharmaceuticals Holdings
Market Cap: US$20.5m
A biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.
RVPH
US$0.29
7D
10.7%
1Y
-78.1%
Cell Source
Market Cap: US$20.4m
A biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance.
CLCS
US$0.42
7D
-5.0%
1Y
40.3%
Finch Therapeutics Group
Market Cap: US$20.2m
A clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
FNCH
US$12.22
7D
0.2%
1Y
6.2%
Allarity Therapeutics
Market Cap: US$19.7m
A clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs.
ALLR
US$1.58
7D
2.6%
1Y
-28.2%
Citius Pharmaceuticals
Market Cap: US$19.6m
A biopharmaceutical company, focuses on the development and commercialization of critical care products.
CTXR
US$1.15
7D
-3.4%
1Y
-91.2%
Harvard Bioscience
Market Cap: US$19.6m
Develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally.
HBIO
US$0.44
7D
-5.3%
1Y
-83.7%
Clearside Biomedical
Market Cap: US$19.5m
A biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
CLSD
US$4.04
7D
7.4%
1Y
-76.8%
Synlogic
Market Cap: US$19.4m
A biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States.
SYBX
US$1.74
7D
-2.2%
1Y
13.7%
Curanex Pharmaceuticals
Market Cap: US$19.2m
A developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases.
CURX
US$0.79
7D
-33.6%
1Y
n/a
Aspire Biopharma Holdings
Market Cap: US$18.7m
An early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States.
ASBP
US$0.36
7D
-12.8%
1Y
-96.9%
Zeo ScientifiX
Market Cap: US$18.6m
A clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines.
ZEOX
US$1.38
7D
-6.3%
1Y
-39.4%
Cellectar Biosciences
Market Cap: US$18.4m
A clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
CLRB
US$5.52
7D
6.2%
1Y
-91.0%
New Green Hemp
Market Cap: US$17.9m
New Green Hemp Inc. cultivates and sells hemp products.
NGHI
US$0.77
7D
0%
1Y
-91.7%
ProPhase Labs
Market Cap: US$17.8m
Develops and commercializes novel drugs, dietary supplements, and compounds in the United States.
PRPH
US$0.44
7D
14.2%
1Y
-81.6%